See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Summary by Endpoints News
New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients with a rare form of high blood pressure in the lungs, potentially providing a boost to sales.

8 Articles

All
Left
Center
2
Right
News MedicalNews Medical
Center

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR…

·United States
Read Full Article
Hastings TribuneHastings Tribune
Reposted by
Merck.comMerck.com
Center

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Mar 31, 2025-

Read Full Article
Managed Healthcare ExecutiveManaged Healthcare Executive

Winrevair Shows Promise in Advancing PAH Treatment

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.

Read Full Article
Endpoints NewsEndpoints News

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients with a rare form of high blood pressure in the lungs, potentially providing a boost to sales.

Read Full Article
healtheconomics.comhealtheconomics.com

Merck's Winrevair Transforms PAH Treatment Landscape with 76% Risk Reduction

Merck’s innovative treatment for pulmonary arterial hypertension (PAH), Winrevair, has demonstrated remarkable efficacy in reducing mortality and morbidity risks by 76%, according to interim results from the phase 3 Zenith trial. This promising outcome prompted the early termination of the study due to its conclusive efficacy, and shortly thereafter, another trial of the first-in-class activin signaling inhibitor followed suit. The Zenith trial …

Read Full Article
ajmc.comajmc.com

Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pulmonary Hypertension News broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

Similar News Topics

Hospitals

Hospitals

Merck

Merck

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal